Baxter International (BAX) to Release Quarterly Earnings on Thursday
Baxter International (NYSE:BAX) will issue its quarterly earnings data before the market opens on Thursday, April 25th. Analysts expect the company to announce earnings of $0.68 per share for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link.
Baxter International (NYSE:BAX) last announced its earnings results on Thursday, January 31st. The medical instruments supplier reported $0.78 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.73 by $0.05. Baxter International had a return on equity of 19.10% and a net margin of 14.60%. The business had revenue of $2.84 billion during the quarter, compared to analysts’ expectations of $2.80 billion. On average, analysts expect Baxter International to post $3 EPS for the current fiscal year and $4 EPS for the next fiscal year.
Shares of BAX stock opened at $76.34 on Wednesday. Baxter International has a fifty-two week low of $61.05 and a fifty-two week high of $82.25. The stock has a market cap of $37.99 billion, a P/E ratio of 25.03, a PEG ratio of 1.79 and a beta of 1.02. The company has a quick ratio of 1.50, a current ratio of 2.09 and a debt-to-equity ratio of 0.44.
BAX has been the subject of several research reports. Morgan Stanley raised Baxter International from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $66.00 to $77.00 in a research note on Wednesday, January 2nd. Citigroup upgraded Baxter International from a “neutral” rating to a “buy” rating and increased their price target for the company from $69.00 to $76.00 in a research report on Wednesday, January 2nd. Zacks Investment Research upgraded Baxter International from a “hold” rating to a “buy” rating and set a $74.00 price target for the company in a research report on Wednesday, January 2nd. Barclays upgraded Baxter International from an “underweight” rating to an “equal weight” rating and increased their price target for the company from $67.00 to $72.00 in a research report on Friday, February 1st. Finally, Piper Jaffray Companies reiterated an “overweight” rating and issued a $80.00 price target on shares of Baxter International in a research report on Friday, February 1st. Five analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $78.12.
In related news, Director Peter S. Hellman sold 5,680 shares of the stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $81.89, for a total value of $465,135.20. Following the completion of the sale, the director now directly owns 28,774 shares of the company’s stock, valued at approximately $2,356,302.86. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Giuseppe Accogli sold 38,297 shares of the stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $76.78, for a total value of $2,940,443.66. Following the completion of the sale, the senior vice president now directly owns 70,001 shares of the company’s stock, valued at $5,374,676.78. The disclosure for this sale can be found here. Insiders sold a total of 95,099 shares of company stock valued at $7,175,949 in the last quarter. 0.70% of the stock is currently owned by corporate insiders.
TRADEMARK VIOLATION WARNING: “Baxter International (BAX) to Release Quarterly Earnings on Thursday” was first reported by Watch List News and is the property of of Watch List News. If you are viewing this report on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The correct version of this report can be accessed at https://www.watchlistnews.com/baxter-international-bax-to-release-quarterly-earnings-on-thursday/2983253.html.
About Baxter International
Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.
Read More: What is the QQQ ETF?
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.